IONQ
HOOD
TRVI

Sonsini Peter W.

Known title: 10% OwnerCIK: 0001559807

Sonsini Peter W.'s purchase track record

Sonsini Peter W. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
4/11/2022TRVI$6.80M+31.3%-36.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 4, 2026

IonQ: Quantum Sector Momentum vs. Fundamentals Debate. Recent coverage focuses on whether the quantum computing rally is driven by real progress or just market momentum. Articles compare IonQ to peers like Rigetti and Alphabet, highlighting how AI and supercomputing integration may give IonQ an edge. While the stock has seen recent gains, analysts continue to debate if current valuations match the company's fundamental growth.

this person other insiders at IONQ

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Wolfe downgrade and CEO stock sale weigh on Robinhood. Robinhood shares fell nearly 9% following a downgrade from Wolfe, a move attributed to shrinking valuation concerns. The stock also faced attention after the CEO sold $43 million in shares, a transaction described as not being what it seems. Implied volatility for Robinhood options is surging, reflecting heightened uncertainty around the stock's future direction.

this person other insiders at HOOD

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 12, 2026

TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.

this person other insiders at TRVI

Transaction History

IONQ▼ Sell$0
IONQ▼ Sell$0
IONQ▼ Sell$0
IONQ▼ Sell$0
IONQ▼ Sell$0
IONQ▼ Sell$0
IONQ▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
TRVI▲ Buy$5.0M
TRVI▲ Buy$1.8M
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
HOOD▼ Sell$0
TRVI▲ Buy—

We use analytics to understand how market-wall is used. No personal data is sold.